AA
CRVS icon

Argent Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Argent Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,000
Closed -$231K – 174
2025
Q4 		$231K Hold
30,000
– – 0.06% 158
2025
Q3 		$221K Hold
30,000
– – 0.07% 156
2025
Q2 		$120K Buy
+30,000
New +$109K 0.04% 150

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Argent Advisors's CRVS Position: Q1 2026 in Review

Argent Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 30,000 shares — an estimated $231K sold.

Argent Advisors first reported a position in CRVS in Q2 2025 and held it in 3 quarters. The position peaked at $231K in Q4 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Argent Advisors reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Argent Advisors sold 30,000 Corvus Pharmaceuticals shares in Q1 2026, an estimated $231K.
  • Argent Advisors first reported a position in Corvus Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Argent Advisors's Corvus Pharmaceuticals position peaked at $231K in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Argent Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.